According to Bill Gates, the FDA has approved the first blood test for diagnosing Alzheimer’s disease, marking a significant advancement in early detection technology (source: Bill Gates on Twitter, May 20, 2025). This development could drive investor interest in biotech stocks, particularly those focused on neurodegenerative disease diagnostics. The approval also signals increased integration of AI and healthcare, which may boost health-focused crypto tokens and blockchain projects aiming to revolutionize medical data management, as easier and earlier diagnosis becomes more feasible.